…
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information for Zenith Capital Corp (ZHCLF.US) on the Pink market is limited, so the company's core business, assets and financial condition are not clearly documented. Long-term prospects therefore depend on management clarifying strategy, access to capital and verified operating results; investors may find upside if substantive disclosures are published.
Key risks include limited disclosure, extremely low trading liquidity, uncertain governance and financial transparency, and increased potential for dilution, volatility or delisting.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
| Income before tax | -7.92M | -7.32M | -10.56M | - | -7.77M |
| Net income | -7.94M | -7.35M | -10.60M | - | -7.80M |
| Selling general administrative | 2.07M | 1.92M | 2.21M | - | 3.33M |
| Gross profit | - | 0.50M | - | - | - |
| Reconciled depreciation | - | - | - | - | 0.19M |
| Ebit | -3.14M | -4.73M | -8.77M | -11.16M | -7.38M |
| Ebitda | -3.02M | -4.63M | -8.61M | - | -7.31M |
| Depreciation and amortization | 0.12M | 0.10M | 0.16M | - | - |
| Operating income | -3.20M | -4.79M | -8.94M | - | -7.38M |
| Other operating expenses | 3.20M | 5.29M | 8.94M | - | - |
| Interest expense | - | 1.58M | - | - | 0.27M |
| Tax provision | - | - | - | - | 0.03M |
| Net interest income | - | - | - | - | -0.51M |
| Income tax expense | 0.02M | 0.03M | 0.03M | 0.02M | 0.03M |
| Total revenue | - | 0.50M | - | - | 0.00M |
| Total operating expenses | 3.20M | 5.29M | 8.94M | - | 7.38M |
| Total other income expense net | -4.72M | -2.52M | -1.62M | - | 0.12M |
| Net income from continuing ops | - | - | - | - | -7.80M |
| Net income applicable to common shares | - | - | - | -13.12M | -7.80M |
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
| Total assets | - | - | 0.01M | - | 2.88M |
| Intangible assets | - | - | 0.00M | - | 0.88M |
| Other current assets | - | - | 0.01M | 0.06M | 0.01M |
| Total liab | - | - | 0.03M | - | 16.72M |
| Total stockholder equity | - | - | -0.02M | - | -13.84M |
| Deferred long term liab | - | - | - | 0.70M | 0.71M |
| Other current liab | - | - | 0.01M | 0.17M | 0.08M |
| Common stock | - | - | 0.09M | 89.62M | 80.94M |
| Capital stock | - | - | - | - | 80.94M |
| Retained earnings | - | - | -0.13M | -118.36M | -105.24M |
| Other liab | - | - | - | 11.35M | 11.35M |
| Other assets | - | - | - | 0.70M | 0.77M |
| Cash | - | - | 0.00M | - | 0.01M |
| Total current liabilities | - | - | 0.01M | 6.68M | 5.36M |
| Current deferred revenue | - | - | 0.00M | - | - |
| Net debt | - | - | 0.01M | - | 3.47M |
| Short term debt | - | - | 0.01M | - | - |
| Short long term debt | - | - | - | - | 3.48M |
| Short long term debt total | - | - | 0.01M | - | - |
| Other stockholder equity | - | - | 0.01M | 2.14M | 0.81M |
| Property plant equipment | - | - | - | 0.10M | 0.22M |
| Total current assets | - | - | 0.01M | 1.38M | 1.00M |
| Net tangible assets | - | - | - | -15.86M | -14.72M |
| Net receivables | - | - | 0.00M | 1.16M | 0.16M |
| Inventory | - | - | 0.00M | 0.11M | 0.30M |
| Accounts payable | - | - | 0.00M | 2.07M | 1.65M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | - | - | 0.00M | - | 0.76M |
| Non current assets total | - | - | 0.00M | - | 1.88M |
| Breakdown | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-04-30 | 2023-04-30 | 2022-04-30 | 2021-04-30 | 2020-04-30 |
| Investments | - | - | -0.26M | -0.25M | -0.37M |
| Change to liabilities | - | 0.34M | 3.48M | -1.78M | 6.40M |
| Total cashflows from investing activities | -0.00M | -0.17M | -0.26M | -0.25M | -0.37M |
| Net borrowings | - | 1.02M | 0.72M | 2.68M | 0.59M |
| Total cash from financing activities | 0.01M | 9.28M | 1.10M | 7.97M | 3.11M |
| Change to operating activities | - | -0.63M | 0.18M | -0.61M | -0.42M |
| Net income | -0.01M | -13.12M | -7.80M | -6.91M | -9.63M |
| Change in cash | 0.00M | 0.02M | 0.00M | -0.21M | 0.01M |
| Begin period cash flow | 0.00M | 0.01M | 0.01M | 0.21M | 0.21M |
| End period cash flow | 0.00M | - | 0.01M | 0.01M | 0.21M |
| Total cash from operating activities | -0.00M | -9.08M | -0.85M | -7.93M | -2.73M |
| Issuance of capital stock | - | - | 0.48M | 5.45M | 2.50M |
| Depreciation | 0.00M | 0.20M | 0.19M | 0.19M | 0.21M |
| Other cashflows from investing activities | -0.00M | 0.02M | -0.09M | 0.07M | -0.05M |
| Dividends paid | - | - | 0.00M | 0.00M | 0.00M |
| Change to inventory | 0.00M | 0.26M | 0.30M | 0.04M | -0.00M |
| Other cashflows from financing activities | 0.00M | -0.19M | -0.14M | -0.17M | -0.02M |
| Change to netincome | - | 3.87M | 2.79M | 1.16M | 0.70M |
| Capital expenditures | 0.00M | 0.00M | 0.16M | 0.32M | 0.01M |
| Change in working capital | 0.00M | - | 3.97M | -2.36M | 6.49M |
| Stock based compensation | 0.00M | - | 2.33M | 1.01M | 0.55M |
| Other non cash items | 0.00M | - | 0.34M | 0.07M | -1.37M |
| Free cash flow | -0.00M | - | -1.01M | -8.25M | -3.05M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ZHCLF Zenith Capital Corp |
- -% |
0.03 | - | - | 54.31 | - | -1.36 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Donald J. McCaffrey | Chairman, Pres & CEO | NA |
| Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV | CFO & Sec. | NA |
| Dr. Sanjay Lakhotia M.B.A., Ph.D. | Chief Bus. Officer | NA |
| Dr. Henrik Claus Hansen Ph.D. | Sr. VP of Operations | NA |
| Dr. Huan Zhu | Chief Medical Officer | NA |
| Mr. Donald J. McCaffrey | Chairman, President & CEO | NA |
| Mr. Aaron Bradley Cann C.A., CPA, CBV | CFO & Secretary | NA |
| Dr. Sanjay Lakhotia M.B.A., Ph.D. | Chief Business Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.